Testing for myotonic dystrophy type 1 usually requires a method designed to detect a CTG repeat expansion in DMPK. A routine negative sequencing result does not necessarily exclude it. The report should identify the method, the repeat-size interpretation and any limits on sizing or detecting large expansions.
DM1 can affect muscles and several other body systems. A genetic result can establish an important part of the diagnosis, but a repeat count alone cannot predict exactly when symptoms will begin or how severe they will become. This guide explains the laboratory terms and the questions to ask next.
What is a CTG repeat?
A short DNA sequence, CTG, is repeated in the untranslated region of DMPK. People naturally differ in how many repeats they carry. An expanded repeat can disrupt cellular processes, including RNA handling. This is different from a single-letter substitution and requires appropriate testing technology.
Swipe or scroll sideways to read all three columns. Keyboard: focus the table, then use Left and Right arrows; Home and End move to either edge.
| Repeat category | Usual interpretation | Important qualification |
|---|---|---|
| 5–34 CTG repeats | Normal range. | Interpret the complete report and the clinical question. |
| 35–49 repeats | Mutable normal / premutation range. | Usually not associated with DM1 manifestations, but may expand when transmitted. |
| 50 or more repeats | Expanded range associated with DM1. | Size is not an exact forecast of age of onset or severity. |
These categories follow the ACMG technical standard. Laboratories may use slightly different wording. Ask for clarification rather than treating a label such as “intermediate” as a diagnosis by itself.
Why a negative exome may not answer the question
Many sequencing tests are designed primarily to detect sequence variants, not to size a large repeat expansion. Some laboratories incorporate validated repeat analysis into broader testing; others do not. The relevant question is therefore “Did this assay assess the DMPK repeat adequately?” rather than simply “Was the DMPK gene on the list?”
Testing approaches can include conventional PCR, repeat-primed PCR and methods for characterising large expansions. Different methods answer different parts of the problem. A report may confirm an expansion without providing a precise count for a very large allele.
A fictional report-reading example
A patient with myotonia receives a negative exome report. The family concludes that DM1 has been excluded. A clinician checks the methods section and finds no validated DMPK repeat-expansion analysis. The appropriate next discussion is about targeted repeat testing and the clinical differential diagnosis, not about disregarding the symptoms.
Now imagine that a targeted test detects an expansion estimated to contain several hundred repeats. The report supports DM1, but it does not identify a specific year when the person will develop a particular complication. Clinical assessment still matters.
Anticipation and mosaicism: why numbers need context
In DM1, repeat instability can contribute to anticipation: disease may present earlier or more severely in a later generation. This is a pattern, not a guarantee for each family. Repeat length can also vary between cells and tissues, so a measurement from blood is not a uniform count in every cell of the body.
These features help explain why a laboratory estimate is not a precise severity scale. They also make counselling about reproductive options and family testing more useful than trying to predict a child’s future from a single parental repeat number.
DM1, DM2 and “CDM” are not interchangeable
DM1 is associated with DMPK. Myotonic dystrophy type 2 is associated with a different repeat expansion in CNBP and requires the relevant assessment. Congenital myotonic dystrophy refers to an early presentation of DM1; the abbreviation “CDM” can also mean other things in medical writing. Read the full term before interpreting a search result or report.
What happens after a positive result?
The clinical discussion extends beyond muscle weakness. GeneReviews describes multisystem assessment and surveillance, including cardiac, respiratory, eye and endocrine considerations. The treating team should tailor care to the person’s findings. Tell relevant clinicians about the diagnosis, especially when planning procedures or anaesthesia.
For relatives, a genetic counsellor can explain inheritance, the meaning of an apparently unaffected family member, and the choices around predictive or reproductive testing. A result in one person should not be used to diagnose every relative without an appropriate discussion and test.
A six-question checklist
- Was this a DMPK CTG repeat test, or another form of genetic analysis?
- What repeat category was found on each allele?
- Was an expansion detected, and how accurately could it be sized?
- Could mosaicism or the test’s technical limits affect the interpretation?
- Which clinical assessments are now appropriate?
- What does the result mean for adult relatives and reproductive planning?
Use the disease finder to locate related guides and Find genetics care to organise a referral. The research tools directory links to resources for reading the underlying evidence.